Dare Bioscience Inc (NAS:DARE)
$ 3.18 -0.01 (-0.31%) Market Cap: 27.75 Mil Enterprise Value: 21.41 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 35/100

Dare Bioscience Inc at ROTH Conference Transcript

Mar 14, 2023 / 03:30PM GMT
Release Date Price: $12.24 (+2.00%)
Kumar Raja
ROTH Capital Partners, LLC - Analyst

Thank you for joining us here today. I am Kumar Raja, Senior Biotech Analyst at ROTH MKM. The next company presenting is Daré Bioscience. We have Sabrina Martucci Johnson, who is the CEO and the President of the company.

Thanks, Sabrina, for joining us. Maybe we can just get started by just giving an overview of the company.

Sabrina Martucci Johnson;Bioscience
DarÃ;Inc. - President & CEO

© -

(inaudible - microphone inaccessible) fertility and menopause, primarily. We have one FDA-approved product now in our portfolio and 10-plus in various stages of development. The late stage programs right now include that FDA-approved product, obviously, that we'll be launching first half of this year.

For condition called bacterial vaginosis we partnered with Organon. We have a Phase 3 program in contraception, first once-a-month hormone-free contraceptive candidate that's in development, and that's partnered with Bayer. And we're looking to start that Phase 3 this year.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot